Target
HER2
Experimental Kd
0.0 nM
- Design the LeadCompleted
- Optimize the LeadCompleted
- In Vitro Binding AssayCompleted
- In Vivo ValidationIn Progress
- Translational & Regulatory StepUpcoming
- Clinical TrialUpcoming
Our lead AI-designed candidates are now being tested in vivo. We are advancing our top programs toward clinical trials.
Pipeline & Show cases
Target
HER2
Experimental Kd
0.0 nM
Target
TROP2
Experimental Kd
0.0 nM
Target
CD38
Experimental Kd
0.0 nM
Target
PD-L1
Experimental Kd
0 nM
The journey
From the first designed lead to the clinic — six stages, one intelligence layer.






Design the Lead
Completed · Q1 2026
Optimize the Lead
Completed · Q1 2026
In Vitro Binding Assay
Completed · Q1 2026
In Vivo Validation
In Progress · Q2 2026
Translational & Regulatory Step
Upcoming · Q3 2026
Clinical Trial
Upcoming · Q4 2026
PharmPhax™
Biological & clinical risk
PharmacoLaw
Legal, patent & regulatory intelligence
Design the Lead
Completed · Q1 2026
Optimize the Lead
Completed · Q1 2026
In Vitro Binding Assay
Completed · Q1 2026
In Vivo Validation
In Progress · Q2 2026
Translational & Regulatory Step
Upcoming · Q3 2026
Clinical Trial
Upcoming · Q4 2026
More programs: Coming Soon…
Contact
Move from disease biology to a collaborative end-to-end program—from target discovery through lead generation—combining Epitorix intelligence with the scientists guiding the development path.